Estimated HCV RNA concentrations of donations infused into chimp X331 to prove susceptibility to HCV infection (experiment II, phase 3)
| Donor/donation no. . | Phase of infection . | Days preceding ramp-up . | No. of TMA-positive replicates (%) . | HCV RNA copies/mL (imputed from replicate TMA testing* or measured by VL assay) . | Infused HCV RNA copies . |
|---|---|---|---|---|---|
| 10083-12 | Prior to ramp-up | 7 | 3/27 (11) | 1.48 (0.71-2.28) | 74 |
| 10083-13 | Prior to ramp-up | 5 | 9/27 (33) | 2.99 (1.83-4.05) | 149 |
| 10083-14 | Ramp-up | 0 | NA† | 6.8 × 105 | 3.4 × 107 |
| Donor/donation no. . | Phase of infection . | Days preceding ramp-up . | No. of TMA-positive replicates (%) . | HCV RNA copies/mL (imputed from replicate TMA testing* or measured by VL assay) . | Infused HCV RNA copies . |
|---|---|---|---|---|---|
| 10083-12 | Prior to ramp-up | 7 | 3/27 (11) | 1.48 (0.71-2.28) | 74 |
| 10083-13 | Prior to ramp-up | 5 | 9/27 (33) | 2.99 (1.83-4.05) | 149 |
| 10083-14 | Ramp-up | 0 | NA† | 6.8 × 105 | 3.4 × 107 |
TMA indicates transcription-mediated amplification; VL, viral load; and NA, not applicable.
RNA copy levels were estimated from probit analysis of replicate testing of the HCV WHO International Standard (NIBSC Codes: 97/690); copies per milliliter were based on a conversion factor of 3.4 RNA copies/IU.
This donation was positive by quantitative HCV RNA testing at a concentration of 6.8 × 105 copies/mL and was not subjected to replicate TMA testing.